Clinical Trial

Evaluating Ivonescimab in PD-1 Resistant Recurrent or Metastatic Nasopharyngeal Carcinoma

Name: Evaluating Ivonescimab in PD-1 Resistant Recurrent or Metastatic Nasopharyngeal Carcinoma — clinical trial record (NCT07565389)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

Study acronym: AK112

Not Yet Recruiting Phase 2

View on ClinicalTrials.gov →

Summary

This study is designed as a single-arm, open-label, phase II trial to evaluate the efficacy and safety of ivonescimab in patients with recurrent or metastatic nasopharyngeal carcinoma (NPC) who have progressed on prior an immune checkpoint inhibitor and platinum-based chemotherapy.

Trial Details

NCT Number	NCT07565389
Lead Sponsor	National University Hospital, Singapore
Conditions	Nasopharyngeal Carcinoma (NPC)
Enrollment	42 participants
Start Date	2026-05
Primary Completion	2031-05 (estimated)
Study Completion	2031-05 (estimated)
Updated on ClinicalTrials.gov	2026-05-04